[{"id":"52425dc1-74c8-49b8-8efe-2388d72e2562","acronym":"","url":"https://clinicaltrials.gov/study/NCT06172296","created_at":"2023-12-15T20:18:48.678Z","updated_at":"2025-02-25T14:04:06.256Z","phase":"Phase 3","brief_title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","source_id_and_acronym":"NCT06172296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • TERT • MYCN","pipe":"","alterations":" ","tags":["ALK • TERT • MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane"],"overall_status":"Recruiting","enrollment":" Enrollment 478","initiation":"Initiation: 04/19/2024","start_date":" 04/19/2024","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-19"},{"id":"4b1b80e8-bcd8-4a78-8ae1-fe238c0362b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03126916","created_at":"2021-01-18T15:24:54.957Z","updated_at":"2025-02-25T15:10:35.328Z","phase":"Phase 3","brief_title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","source_id_and_acronym":"NCT03126916","lead_sponsor":"Children's Oncology Group","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 724","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"f18181fc-ba3a-410b-9369-091830924976","acronym":"","url":"https://clinicaltrials.gov/study/NCT05457556","created_at":"2022-09-07T16:55:34.255Z","updated_at":"2025-02-25T15:12:56.234Z","phase":"Phase 3","brief_title":"Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT05457556","lead_sponsor":"Children's Oncology Group","biomarkers":" FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3 • ABL1 • BCR • NPM1 • HLA-DRB1 • CEBPA • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • methotrexate • melphalan • Truxima (rituximab-abbs) • fludarabine IV • thiotepa • busulfan • Mabtas (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 435","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-13"},{"id":"0f0a2dc6-cfa3-4fe4-b319-c5a4a3207380","acronym":"FRE","url":"https://clinicaltrials.gov/study/NCT05824689","created_at":"2023-04-21T15:04:43.422Z","updated_at":"2025-02-25T15:36:10.840Z","phase":"","brief_title":"Fluoroquinolone Resistance Prevalence Study","source_id_and_acronym":"NCT05824689 - FRE","lead_sponsor":"Hackensack Meridian Health","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 07/08/2022","start_date":" 07/08/2022","primary_txt":" Primary completion: 12/17/2024","primary_completion_date":" 12/17/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-10"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"c6706368-4b51-4cd8-9e6f-57a4d3ecf646","acronym":"","url":"https://clinicaltrials.gov/study/NCT01526096","created_at":"2021-01-18T06:26:01.906Z","updated_at":"2025-02-25T16:43:39.104Z","phase":"Phase 1","brief_title":"Stem Cell Transplantation for Patients With Multiple Myeloma","source_id_and_acronym":"NCT01526096","lead_sponsor":"University of Chicago","biomarkers":" IL2RA • CD4 • FOXP3 • ISG20","pipe":"","alterations":" ","tags":["IL2RA • CD4 • FOXP3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • plerixafor"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 07/12/2011","start_date":" 07/12/2011","primary_txt":" Primary completion: 09/12/2025","primary_completion_date":" 09/12/2025","study_txt":" Completion: 09/12/2025","study_completion_date":" 09/12/2025","last_update_posted":"2025-02-05"},{"id":"3615e982-327f-4793-b8ff-fdb95f9f33a8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03856216","created_at":"2021-01-18T19:01:48.041Z","updated_at":"2025-02-25T16:52:26.547Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","source_id_and_acronym":"NCT03856216","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD22 • HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD22 • HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • methotrexate • Besponsa (inotuzumab ozogamicin) • bendamustine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"bb6fe11c-92d7-43aa-a535-cfa2d75b128c","acronym":"CNS-PHLAT","url":"https://clinicaltrials.gov/study/NCT06687772","created_at":"2025-02-25T19:05:14.187Z","updated_at":"2025-02-25T19:05:14.187Z","phase":"Phase 2","brief_title":"CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant","source_id_and_acronym":"NCT06687772 - CNS-PHLAT","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carmustine • melphalan • thiotepa"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/16/2025","start_date":" 01/16/2025","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 07/31/2029","study_completion_date":" 07/31/2029","last_update_posted":"2025-01-22"},{"id":"c2530d5f-2067-4089-83d8-8b338ff98d19","acronym":"","url":"https://clinicaltrials.gov/study/NCT06245629","created_at":"2025-02-26T11:14:39.219Z","updated_at":"2025-02-26T11:14:39.219Z","phase":"","brief_title":"Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma","source_id_and_acronym":"NCT06245629","lead_sponsor":"Uppsala University","biomarkers":" SLC1A5","pipe":"","alterations":" ","tags":["SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • bendamustine • melphalan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/24/2024","start_date":" 11/24/2024","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-11-28"},{"id":"fd746a04-cf2a-4fe6-8ac1-71be01980b12","acronym":"","url":"https://clinicaltrials.gov/study/NCT03016806","created_at":"2021-01-18T14:50:46.648Z","updated_at":"2025-02-25T14:14:55.178Z","phase":"Phase 1","brief_title":"Umbilical Cord Blood Transplantation From Unrelated Donors","source_id_and_acronym":"NCT03016806","lead_sponsor":"University of Rochester","biomarkers":" FLT3 • KMT2A","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement","tags":["FLT3 • KMT2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2015","start_date":" 06/01/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2024-08-19"},{"id":"61e57503-680e-4667-ac9e-45a1209fdaaf","acronym":"TT4B","url":"https://clinicaltrials.gov/study/NCT00734877","created_at":"2021-01-18T02:46:06.475Z","updated_at":"2025-02-25T14:55:10.781Z","phase":"Phase 3","brief_title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","source_id_and_acronym":"NCT00734877 - TT4B","lead_sponsor":"University of Arkansas","biomarkers":" TP53","pipe":" | ","alterations":" TP53 deletion","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • dexamethasone • thalidomide • melphalan"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 382","initiation":"Initiation: 07/01/2008","start_date":" 07/01/2008","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-07-03"},{"id":"ea8aa5eb-747e-43c1-9888-86c7239699c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00547196","created_at":"2021-01-18T01:59:32.370Z","updated_at":"2024-07-02T16:34:25.798Z","phase":"","brief_title":"AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies \u0026 Disorders","source_id_and_acronym":"NCT00547196","lead_sponsor":"City of Hope Medical Center","biomarkers":" KMT2A • HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/16/2005","start_date":" 08/16/2005","primary_txt":" Primary completion: 11/11/2009","primary_completion_date":" 11/11/2009","study_txt":" Completion: 05/28/2024","study_completion_date":" 05/28/2024","last_update_posted":"2024-06-14"},{"id":"74c31265-1520-4843-8d42-dcf55e82cdf5","acronym":"TSCAN-001","url":"https://clinicaltrials.gov/study/NCT05473910","created_at":"2022-07-26T17:09:59.782Z","updated_at":"2024-07-02T16:34:26.524Z","phase":"Phase 1","brief_title":"A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation","source_id_and_acronym":"NCT05473910 - TSCAN-001","lead_sponsor":"TScan Therapeutics, Inc.","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • HLA-A positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • TSC-100 • TSC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-13"},{"id":"6c8187f2-a1a7-4e0d-9839-99324cab5154","acronym":"","url":"https://clinicaltrials.gov/study/NCT06022939","created_at":"2023-09-05T18:12:25.015Z","updated_at":"2024-07-02T16:34:27.373Z","phase":"Phase 3","brief_title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","source_id_and_acronym":"NCT06022939","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD34","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • cyclophosphamide • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • dexamethasone injection"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 338","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 07/29/2030","primary_completion_date":" 07/29/2030","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2024-06-11"},{"id":"fe8da34f-8155-4e53-a434-b93819c389c5","acronym":"OPTIMIZE","url":"https://clinicaltrials.gov/study/NCT06001385","created_at":"2023-08-21T14:08:42.896Z","updated_at":"2024-07-02T16:34:27.204Z","phase":"Phase 2","brief_title":"HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis","source_id_and_acronym":"NCT06001385 - OPTIMIZE","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 12/08/2023","start_date":" 12/08/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-06-11"},{"id":"75104445-162f-444f-84ea-8038034ab832","acronym":"","url":"https://clinicaltrials.gov/study/NCT02727803","created_at":"2021-01-18T13:21:10.406Z","updated_at":"2024-07-02T16:34:36.895Z","phase":"Phase 2","brief_title":"Personalized NK Cell Therapy in CBT","source_id_and_acronym":"NCT02727803","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • BCL2","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/19/2016","start_date":" 05/19/2016","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-06-10"},{"id":"7026c02a-02d2-4eaf-9842-da3071018ea9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02443077","created_at":"2021-01-18T11:42:20.749Z","updated_at":"2024-07-02T16:34:37.048Z","phase":"Phase 3","brief_title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT02443077","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1","pipe":" | ","alterations":" CD79A mutation + CD79B mutation","tags":["MYC • BCL2 • BCL6 • TNFA • CARD11 • TNFAIP3 • CD79A • GSTT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79A mutation + CD79B mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 302","initiation":"Initiation: 10/12/2016","start_date":" 10/12/2016","primary_txt":" Primary completion: 05/10/2025","primary_completion_date":" 05/10/2025","study_txt":" Completion: 05/10/2025","study_completion_date":" 05/10/2025","last_update_posted":"2024-06-07"},{"id":"a652e199-25c7-474e-ae48-fce734badcf9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03579875","created_at":"2021-01-18T17:36:44.603Z","updated_at":"2024-07-02T16:34:37.677Z","phase":"Phase 2","brief_title":"Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders","source_id_and_acronym":"NCT03579875","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/05/2029","study_completion_date":" 01/05/2029","last_update_posted":"2024-06-06"},{"id":"92222cde-38f1-4798-9e7b-0b2b4361f314","acronym":"","url":"https://clinicaltrials.gov/study/NCT05436418","created_at":"2022-06-29T15:59:10.686Z","updated_at":"2024-07-02T16:34:38.201Z","phase":"Phase 1/2","brief_title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","source_id_and_acronym":"NCT05436418","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IGH • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["IGH • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 11/18/2022","start_date":" 11/18/2022","primary_txt":" Primary completion: 06/25/2027","primary_completion_date":" 06/25/2027","study_txt":" Completion: 07/02/2027","study_completion_date":" 07/02/2027","last_update_posted":"2024-06-05"},{"id":"2389ac55-3a18-481d-8919-40b11f2cb668","acronym":"NCI-2017-01069","url":"https://clinicaltrials.gov/study/NCT03192397","created_at":"2021-01-18T15:44:50.740Z","updated_at":"2024-07-02T16:35:00.229Z","phase":"Phase 1/2","brief_title":"Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant","source_id_and_acronym":"NCT03192397 - NCI-2017-01069","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • melphalan • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/09/2017","start_date":" 08/09/2017","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 05/21/2027","study_completion_date":" 05/21/2027","last_update_posted":"2024-05-29"},{"id":"d888b6c9-4b44-4498-aef7-22dac96f744f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01163357","created_at":"2021-01-18T04:38:10.114Z","updated_at":"2024-07-02T16:35:00.426Z","phase":"Phase 1","brief_title":"Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma","source_id_and_acronym":"NCT01163357","lead_sponsor":"City of Hope Medical Center","biomarkers":" HLA-DRB1","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bortezomib • sirolimus • melphalan • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/28/2011","start_date":" 01/28/2011","primary_txt":" Primary completion: 07/20/2019","primary_completion_date":" 07/20/2019","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-29"},{"id":"cd5cf9d3-98a9-4678-a914-8b4e2b5f403f","acronym":"ACCESS","url":"https://clinicaltrials.gov/study/NCT04904588","created_at":"2021-05-27T12:53:04.457Z","updated_at":"2024-07-02T16:35:01.309Z","phase":"Phase 2","brief_title":"HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide","source_id_and_acronym":"NCT04904588 - ACCESS","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-DPB1 • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-DPB1 • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 09/30/2021","start_date":" 09/30/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-05-23"},{"id":"1d61c822-8b23-4a8f-b429-8c238d66ec51","acronym":"HR-NBL2","url":"https://clinicaltrials.gov/study/NCT04221035","created_at":"2021-01-18T20:32:43.345Z","updated_at":"2024-07-02T16:35:03.584Z","phase":"Phase 3","brief_title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","source_id_and_acronym":"NCT04221035 - HR-NBL2","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","biomarkers":" MYCN • MYCL","pipe":" | ","alterations":" MYCN amplification • MYCL amplification","tags":["MYCN • MYCL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification • MYCL amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dacarbazine • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • cyclophosphamide intravenous • vindesine"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 11/05/2019","start_date":" 11/05/2019","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2024-05-15"},{"id":"b2fc6887-a084-4aa0-93a1-942ca0ac28d0","acronym":"MUKnineb","url":"https://clinicaltrials.gov/study/NCT03188172","created_at":"2021-01-18T15:43:10.893Z","updated_at":"2025-02-25T14:26:26.313Z","phase":"Phase 2","brief_title":"MUK Nine b: OPTIMUM Treatment Protocol","source_id_and_acronym":"NCT03188172 - MUKnineb","lead_sponsor":"University of Leeds","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • cyclophosphamide • Darzalex (daratumumab) • dexamethasone • melphalan • Neupogen (filgrastim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 09/28/2017","start_date":" 09/28/2017","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-05-14"}]